HealthcareMid capRs 7,407 crRs 18.6 cr traded a day
Close on 2026-08-21
816.80
−1.50%
52-week range65% of the way up
591.95939.50
Market cap
7,407 cr
P/E (TTM)
34.7×
industry 44×
EPS (TTM)
23.51
Revenue YoY
+38.7%
Q1 FY27
Profit YoY
+53.8%
Net margin
14.2%
+1.4pt vs a year ago
Growth trend
+35.4pt
vs last quarter’s YoY
1 month
+23.8%
Below 52w high
15.0%
RSI (14)
70
Daily swing
5.6%
average true range
Volume
0.4×
vs 20-day average
Traded
Rs 19 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−4.04%
1 month
+23.80%
3 months
+17.59%
6 months
+13.49%
1 year
−6.14%
The read
written from the numbers on this page
The evidence leans constructive4 supporting, 1 against, 1 worth knowing
Supporting
trading 15% above its 200-day average
revenue grew 39% year on year in the quarter ending 2026-06-30
net margin has widened from 6.7% to 14.2% across four quarters
priced at 35× earnings against an industry median of 44× — 21% below its peers
Against
down 6% over twelve months
Worth knowing
the 7 scans it matches come from only 2 families — one signal wearing several hats rather than several signals
What would change this read: a close below 712, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +53.8% year on year, Rs 50 cr to Rs 76 cr.
+53.8%Rs 50 crRs 76 cr
Revenue +38.7% year on year, Rs 386 cr to Rs 536 cr.
+38.7%Rs 386 crRs 536 cr
Profit grew faster than revenue, +53.8% against +38.7%.
+53.8%+38.7%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
7 of 47 matched on 2026-08-21
AARTIPHARM matches 7 of the 47 scans today, across 2 different kinds of evidence. Note how few kinds of evidence that is: several scans in one family are one signal wearing several hats, not several signals.
AARTIPHARM trades at 35× trailing earnings, above its median of 28× over this window — 22% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 39% against the same quarter a year earlier
profit rose 54% year on year
net margin widened from 10.5% to 14.2%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
536
94
76
8.40
14.2%
Q4 FY26
2026-03-31 · consolidated
583
76
61
6.74
10.5%
Q3 FY26
2025-12-31 · consolidated
432
58
48
5.29
11.1%
Q2 FY26
2025-09-30 · consolidated
418
39
28
3.08
6.7%
Q1 FY26
2025-06-30 · consolidated
386
67
50
5.46
12.8%
Q4 FY25
2025-03-31 · consolidated
564
115
88
9.75
15.7%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+13.3%
Versus 200-day average+14.7%
Below 52-week high-13.1%
Above 52-week low+38.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)69.7
Higher closes in last 52 of 5
Six-month return+13.49%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)5.60%
Volume versus 20-day0.4x
Median daily turnoverRs 18.6 cr
Peers
Healthcare · 67 classified companies
AARTIPHARM trades at 34.7× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 21%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.